Shield Therapeutics
plc
("Shield Therapeutics" or the
"Company")
PDMR Transaction
Notification
London, UK, 13 February 2025: Shield Therapeutics plc (LSE:STX), a commercial stage
pharmaceutical company specialising in iron deficiency, confirms
that Mr Anders Lundstrom, Chief Executive Officer, acquired 575,000
Ordinary Shares in the Company on 13 February 2025 at a price of
3.7p per share. Mr Lundstrom now holds a beneficial interest in
585,000 Ordinary Shares.
The notification below, which has
been made in accordance with the requirements of the EU Market
Abuse Regulation, provides further detail.
Notification and public
disclosure of transactions by persons discharging managerial
responsibilities and persons closely associated with
them:
|
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a.
|
Name
|
Anders Lundstrom
|
|
2.
|
Reason for the notification
|
|
a.
|
Position/status
|
Chief Executive Officer
|
|
b.
|
Initial notification
/Amendment
|
Initial
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a.
|
Name
|
Shield Therapeutics plc
|
|
b.
|
LEI
|
213800G74QWY15FC3W71
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a.
|
Description of the
Financial instrument,
type
of instrument
Identification code
|
Ordinary shares of 1.5p each in the
capital of the Company
ISIN of Ordinary Shares:
GB00BYV81293
|
|
b.
|
Nature of the transaction
|
Acquisition of Ordinary
Shares
|
|
c.
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
3.7p
|
575,000
|
|
|
d.
|
Aggregated information
· Aggregated
volume
· Price
|
575,000
£21,275
|
|
e.
|
Date of the transaction
|
13 February 2025
|
|
f.
|
Place of the transaction
|
AIM
|
For further
information please contact:
|
Shield Therapeutics plc
|
www.shieldtherapeutics.com
|
|
Anders Lundstrom, CEO
|
+44 (0)
191 511 8500
|
|
Santosh Shanbhag, CFO
Stephanie Hicks, Investor
Relations
|
Investorrelations@shieldtx.com
|
|
|
|
|
Nominated Adviser and Joint Broker
|
|
|
Peel Hunt LLP
|
|
|
James Steel / Patrick
Birkholm
|
+44 (0)20
7418 8900
|
|
|
|
|
Joint Broker
|
+44 (0)20
7220 0500
|
|
Cavendish Ltd
|
|
|
Geoff Nash / Rory Sale / Nigel Birks
/ Harriet
Ward
|
|
|
|
|
|
Financial PR & IR Advisor
|
|
|
Walbrook PR
|
|
|
Alice Woodings / Lianne
Applegarth
|
+44 (0)20
7933 8780 or shield@walbrookpr.com
|
About Iron Deficiency and
ACCRUFeR®/FeRACCRU®
Clinically low iron levels (aka iron
deficiency, ID) can cause serious health problems for adults of all
ages, across multiple therapeutic areas. Together, ID and ID with
anemia (IDA) affect about 20 million people in the US and represent
a $2.3B market opportunity. As the first and only FDA approved oral
iron to treat ID/IDA, ACCRUFeR® has the potential to meet an
important unmet medical need for both physicians and
patients.
ACCRUFeR®/FeRACCRU® (ferric maltol)
is a novel, stable, non-salt-based oral therapy for adults with
ID/IDA. The drug has a novel mechanism of absorption compared to other oral
iron therapies and has been shown to be an efficacious and
well-tolerated therapy in a range of clinical trials. More
information about ACCRUFeR®/FeRACCRU®, including the product
label, can be found at: www.accrufer.com and www.feraccru.com.
About Shield Therapeutics plc
Shield is a commercial stage
specialty pharmaceutical company that delivers ACCRUFeR®/FeRACCRU®
(ferric maltol), an innovative and differentiated pharmaceutical
product, to address a significant unmet need for patients suffering
from iron deficiency, with or without anemia. The Company has launched ACCRUFeR® in the U.S. with an
exclusive, multi-year collaboration agreement with Viatris Inc.
Outside of the U.S., the Company has licensed the rights to four
specialty pharmaceutical companies. FeRACCRU® is commercialized in
the UK and European Union by Norgine B.V., which also has marketing
rights in Australia and New Zealand. Shield also has an exclusive
license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd.,
for the development and commercialization of ACCRUFeR®/ FeRACCRU®
in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd.
for the Republic of Korea, and with KYE Pharmaceuticals Inc. for
Canada.
ACCRUFeR®/FeRACCRU® has patent
coverage until the mid-2030s.
ACCRUFeR®/FeRACCRU® are registered
trademarks of Shield Therapeutics.
